Recent news on Viread

THERE ARE MANY STORIES TO TELL ABOUT AIDS PANDEMIC  -  May 23, 2007
VUE Weekly,These drugs, marketed under the names Viread and Truvada, contain a cocktail of several active ingredients known as nucleotide analogue reverse

Gilead to launch generic Viread  -  May 11, 2007
Economic Times,NEW DELHI: US-based biopharmaceutical firm Gilead Sciences on Friday will launch generic versions of its HIV/AIDS drug 'Viread' in the next 3-6 months

Gilead pushes for patent for HIV drug in India  -  May 11, 2007
Scientific AmericanNEW DELHI (Reuters) - Gilead Sciences Inc. will cancel its deal with Indian drug makers to produce cheaper copies of its HIV drug, Viread, if it does not

California pharma firm banks on Indian companies  -  May 14, 2007
People's Daily Online,The agreements cover two drugs, Emtriva (emtricitabine) and Viread (tenofovirdisproxil fumarate), and allows the Indian partners to make any combination of

New drug kills cancer cells  -  May 3, 2007
Prague Post,In 2001, the American Food and Drug Administration approved Viread, an anti-HIV drug that Holý and De Clercq developed. The drug can stop HIV from infecting

Progenics' Intriguing Study Results  -  May 2, 2007
Motley FoolAs a comparison, Gilead's (Nasdaq: GILD) HIV treatment Viread -- which received marketing approval in 2001 -- reduced HIV viral loads by an average of 1.5

Doctors, life-saving drugs and the poor  -  May 17, 2007
Bangkok Post,Gilead Sciences has granted licences to generic manufacturers to supply its blockbuster HIV drug, Viread, to the world's hundred poorest countries at the

Pharmaceutical Companies Should 'Broaden' Efforts To Provide ...  -  May 17, 2007
Kaiser network.org,Gilead Sciences has granted licenses to generic drug makers to develop its antiretroviral Viread in the world's 100 poorest nations for a royalty of 5% of

Gilead Sciences counts on Indian pharma companies  -  May 13, 2007
Moneycontrol.com,The agreements entered into since last September cover two drugs, Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), and allows the Indian

APN - Aspen - Key Arv Products Viread* And Truvada* Registered By Mcc  -  Apr 24, 2007
Finance24,Both Viread and Truvada have extensive usage in North America, Europe and some African countries. Last week both products were included in the World Health

Gilead earnings, revenue beat expectations  -  Apr 18, 2007
CNNMoney.comGilead chief operating officer John Milligan said, on a call with analysts and reporters, that earnings were driven by HIV drugs Atripla, Truvada and Viread

Gilead Sciences profit surges 55%  -  Apr 18, 2007
MarketWatchThe FDA approved Atripla, made up of Gilead's Truvada -- which consists of the company's drugs Viread and Emtriva -- and Bristol-Myers Squibb Co.'s (BMY :

Gilead quarterly profit, revenue seen up 43%  -  Apr 17, 2007
MarketWatchViread and Emtriva sales, meanwhile, are expected to slip sequentially, to $157.9 million and $8.4 million from fourth-quarter results of $159.5 million and

AIDS drug maker for the world producing around the clock at city plant  -  Apr 13, 2007
Edmonton Journal (subscription),You will see bulk quantities of a powder called Viread, Gilead's HIV cornerstone drug, heading out to all parts of the world.

Gilead's revenue and profit up in Q1  -  Apr 19, 2007
Bizjournals.com,Sales of the HIV drugs Viread and Emtriva both fell 16 percent during the quarter. Gilead also sold drugs for Hepatitis B and for severe fungal infections

Gilead Sciences maakt eerstekwartaalcijfers 2007 bekend  -  Apr 19, 2007
Netherlands Corporate News (persbericht),Viread Sales of Viread(R) (tenofovir disoproxil fumarate) were $160.7 million in the first quarter of 2007, a 16 percent decrease from $191.8 million in the

FDA panel backs Pfizer HIV drug  -  Apr 24, 2007
BusinessWeekBy comparison, Gilead Science's top-selling HIV drug, Viread, posted $689 million in sales last year. At least 1 million people in the United States have

Gilead's Sales are Galloping Ahead  -  Apr 24, 2007
Motley FoolWith Gilead, the most important part of its operations are its HIV franchise drugs like Truvada, Atripla, and Viread. In total, sales of these combination

Gilead Q1 Profit Soars 55% On Strong HIV Drug Sales  -  Apr 18, 2007
Trading Markets,Gilead's portfolio of HIV drugs includes Truvada, Atripla, Viread and Emtriva. The company's HIV product sales for the recent first quarter was $705.1

3 More Kings of Cash  -  Apr 23, 2007
Motley FoolAs the world's leader in HIV treatments, Gilead's dominant franchise of products (Altripla, Truvada, Viread, and Emtriva), lengthy patent protection,

Feature Story  -  Apr 20, 2007
Investor's Business Daily (subscription)...an all-time high on Friday, two days after the biotech beat views by 6 cents, thanks largely to higher sales of HIV drugs Truvuda, Viread and Atripla.

Zacks Analyst Blog Highlights: Tweeter, Best Buy, Gilead Sciences ...  -  Apr 20, 2007
Business Wire (press release),The product combines Gilead's Truvada, itself a fixed-dose combination of Viread and Emtriva, and Sustiva, a non-nucleoside reverse transcriptase inhibitor

Analysis: Gilead's future looks bright  -  Apr 19, 2007
United Press InternationalHe said he anticipates Atripla will be used as first-line treatment for HIV infection, and patients will be switched to Truvada and Viread as they develop

Gilead first quarter profit rises 55 pct  -  Apr 18, 2007
ReutersFirst-quarter sales of Viread and Emtriva, the two older HIV drugs used in the combination pills, fell 16 percent to $160.7 million and by 16 percent to

HIV drugs should give big boost to Gilead  -  Apr 18, 2007
CNNMoney.comBut part of the new product sales growth comes from the "cannibalization" of Gilead's older HIV drug Viread, which should experience a modest sales decline

Earnings Preview: Gilead Sciences  -  Apr 16, 2007
Forbes,Also, sales of Atripla are expected to grow throughout the year, but could eat into sales of Gilead's other HIV drugs Viread and Truvada.

Gilead shifts Irish ops  -  Apr 13, 2007
BiopharmaReporter.com,...the only once-daily single tablet regimen for HIV-1 infection, Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (emtricitabine and

Gilead Sciences: Rapid Growth Expected From New Products  -  Apr 3, 2007
Seeking Alpha,...and continued strong performance of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate),

d4T dose can be reduced without loss of effectiveness, meta ...  -  Apr 2, 2007
Aidsmap,The critical piece of evidence that led to the abandonment of d4T in the developed world came from the Gilead 903 study, which compared tenofovir (Viread)

Standard screening tests may not detect hidden hepatitis B virus ...  -  27 Mar 2007
Aidsmap,...with occult hepatitis B were taking antiretroviral drugs with anti-HBV activity, such as 3TC (Epivir), emtricitabine (Emtriva), or tenofovir (Viread).

PUBPAT Takes on Key HIV/AIDS Drug Patents  -  27 Mar 2007
ag-IP-news Agency,Gilead markets TDF in the United States under the brand name Viread and as a part of its Atripla combination product. "Every person afflicted with HIV/AIDS

Gilead CEO Martin Receives $13.7 Million  -  Mar 23, 2007
Forbes,...based Gilead, which makes HIV drugs Truvada, Viread and Emtriva as well as partnering with Bristol-Myers Squibb (nyse: BMY - news - people ) on the

Gilead CEO Martin Receives $13.7 Million  -  Mar 23, 2007
Houston Chronicle,...based Gilead, which makes HIV drugs Truvada, Viread and Emtriva as well as partnering with Bristol-Myers Squibb on the combination HIV drug Atripla,

New HIV listings added to Pharmaceutical Schedule  -  Mar 14, 2007
Scoop.co.nz,Viread as well as Emtriva are for use in combination with other HIV medications for the treatment of HIV infection in adults. Viread is provided as a tablet

Ahead of the Bell: Merrill Ups Gilead  -  Mar 20, 2007
Forbes,Ende also touted the company's HIV treatments, which include Viread and Emtriva. "We view Gilead's HIV franchise as solid with a relatively low risk of

Gilead promotes two execs, including CFO  -  Mar 10, 2007
Bizjournals.com,Gilead sells the antiretroviral drugs Truvada, Viread and Emtriva. Viread has been sold in the United States since 2001, Emtriva since 2003 and Truvada

CDC: AIDS drugs hold promise for prevention  -  Mar 1, 2007
Inside Bay Area,But it might be a public health breakthrough if high doses of Viread and Emtriva are proven to be useful in protecting people from the AIDS virus, HIV.

HIV drugs to be subsidised  -  Mar 15, 2007
New Zealand Herald,The medicines, Tenofovir (Viread) and Emtricitabine (Emtriva), will be subsidised from April 1. Pharmac medical director Peter Moodie said the investment

Pharmac's new HIV drugs too slow - Aids foundation  -  Mar 14, 2007
Stuff.co.nz,Pharmac today announced two new medicines, Tenofovir (Viread) and emtricitabine (Emtriva), would be subsidised from April 1, 2007.

Two new medicines funded for people with HIV  -  Mar 14, 2007
Scoop.co.nz,Tenofovir (Viread) and emtricitabine (Emtriva) are comparatively new treatments that have similar actions to anti-HIV medicines that are already funded.

New HIV meds funded after delay  -  Mar 14, 2007
Scoop.co.nz,The New Zealand AIDS Foundation is welcoming PHARMAC’s decision to fund two more anti-retroviral treatments for HIV from April 1, tenofovir (Viread) and

How do ARVs work?  -  Mar 25, 2007
ZimDaily,...eg Efavirenz may be called Stocrin, Nevirapine Virimune, Tenofovir Viread, and Lopinavir/ritonavir may be called Kaletra (capsules) or Aluvia (tablets).

CROI: high burden of side-effects from d4T leads to WHO dose ...  -  Mar 21, 2007
Aidsmap,Of note is the very low switch rate from tenofovir (Viread), which was used as part of the first-line regimen in Uganda.

Management Reshuffles - Weekly Recap  -  Mar 11, 2007
Trading Markets,According to analyst Shiv Kapoor, both Truvada and Viread products are unlikely to witness competition over the next several years.

CROI: Is tenofovir causing kidney problems?  -  Mar 13, 2007
Aidsmap,Tenofovir (Viread) has been associated with kidney (renal) toxicity in certain cases, although this has proven to be nearly always mild, rare,

CROI: Is there a ceiling to CD4 recovery on virologically ...  -  Mar 13, 2007
Aidsmap,Those on any combination containing tenofovir (Viread) (average 39 to 44 cells/mm 3 /year less compared to stavudine (Zerit), p = 0.015).

CROI: High rate of virologic failure on once-daily combination of ...  -  Mar 8, 2007
Aidsmap,200 mg) and Combivir (300 mg AZT plus 150 mg 3TC) to a once-daily combination of 300 mg 3TC, 400 mg nevirapine, and 245 mg tenofovir (Viread).

Czech scientists claim US drugmaker shelving powerful new drug  -  Mar 7, 2007
Monsters and Critics.com,US drugmaker Gilead Sciences markets as Viread and Hepsera, the new substance named MK 612 is much more effective and less toxic than its predecessors.

Anti-HBV drug entecavir also active against HIV and promotes ...  -  Mar 1, 2007
Aidsmap,Further, two approved anti-HIV drugs -- emtricitabine (Emtriva) and tenofovir (Viread) – are also active against HBV, and are in clinical trials for this

South Africa: Aspen's Operating Profit Lifts On Aids Drugs Sales  -  Feb 27, 2007
AllAfrica.com,He said Aspen hoped to get two second-line AIDS treatments, Truvada and Viread, registered with the Medicines Control Council by mid-year, and manufacture

Aspen revenue almost R2billion  -  Feb 26, 2007
Business Day,There’s the export business that’s grown well over 50% - let’s call that non-South African ARVs, where there’s big growth with the registration of Viread

CROI: Alendronate effectively treats bone loss in men and women ...  -  Feb 26, 2007
Aidsmap,About 65% were taking protease inhibitors and 38% were taking tenofovir (Viread), which has been linked with bone loss in some studies.

Aspen posts solid H1 results, headline EPS rise 11%  -  Feb 26, 2007
Engineering News (press release),Viread and Truvada, originator products, which were second line treatments, would both be launched into African markets by Aspen before the end of the

Aspen pumps up earnings 11%  -  Feb 26, 2007
iAfrica.com,Viread and Truvada, originator products which are leading second line treatments, will both be launched into African markets by Aspen before the end of the

APN - Aspen - Interim financial results: six months ended 31 ...  -  Feb 26, 2007
Finance24,Viread and Truvada, originator products which are leading second-line treatments, will both be launched into African markets before the end of the financial

Gilead Sciences "buy"  -  Feb 22, 2007
newratings.comThe company’s lead Nucleoside Reverse Transcriptase Inhibitor (NRTI), Viread, is expected to continue to capture market share from other NRTI's.

Merck & Co., Inc. To Distribute ATRIPLA™ in Developing Countries  -  Feb 16, 2007
WebWire (press release),Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva® and Viread®, respectively.

Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing ...  -  Feb 16, 2007
Genetic Engineering News (press release),Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively.

Cipla lends support to anti-patent drive  -  Feb 14, 2007
Economic Times,MUMBAI: Domestic pharma major Cipla is opposing US-based biotech major Gilead Sciences’ patent application in India for anti-AIDS drug Viread.

Corporate Globalization Kills  -  Feb 18, 2007
Infoshop NewsIn another significant court case, the US-based Gilead Sciences has attempted to press its claim for a patent for its antiretroviral drug Viread in India,

Merck to sell AIDS pill in poor countries  -  Feb 20, 2007
Philadelphia Business Journal,The tablet combines three drugs in one pill -- Viread and Emtriva from Gilead, and Sustiva from Bristol-Myers Squibb Co. (NYSE:BMY) of New York.

Gilead Sciences swings to quarterly loss  -  Jan 31, 2007
MarketWatchThe FDA approved Atripla, which contains Bristol-Myers' Sustiva and Gilead's Truvada, which itself consists of the company's drugs Viread and Emtriva,

Gilead Sciences meldt financiële resultaten kw4 en jaar 2006  -  Jan 31, 2007
Netherlands Corporate News (persbericht),Viread Viread sales were $159.5 million in the fourth quarter of 2006, a 13 percent decrease from $182.4 million in the fourth quarter of 2005.

Strong quarter boosts Gilead  -  Feb 12, 2007
Blogging StocksHe explains, "Gilead's HIV treatments (Viread, Truvada, Atripla, and Emtriva) were clear winners, with sales growing 67% to $642.4 million and surpassing

Gilead Posts 4Q Loss on Buyout Charges  -  Jan 31, 2007
Houston Chronicle,Sales of Viread fell 13 percent to $159.5 million, compared with $182.4 million in the fourth quarter of 2005, as patients switched from drug regimens

Earnings Preview: Gilead Sciences  -  Jan 29, 2007
Forbes,The company sells antiretrovirals Truvada, Viread and Emtriva and makes two of the three components to Atripla. BY THE NUMBERS: Analysts polled by Thomson

Gilead's Gold Mine  -  Feb 5, 2007
Motley Fool...though, since key patents for its top drugs like the flu treatment Tamiflu and the HIV treatment Viread won't expire until 2016 and 2017, respectively.

Zacks Analyst Blog Highlights: Home Depot, Lowe’s, Gilead Sciences ...  -  Feb 22, 2007
Business Wire (press release),We consider Truvada a reformulation of drugs Viread and Emtriva to be a potential breakthrough product for the treatment of HIV/AIDS.

Merck files triple-therapy HIV treatment in poorest countries  -  Feb 19, 2007
Pharma Times (subscription),...is delivered in a single tablet, and combines Bristol-Myers Squibb's Sustiva (efavirenz) and Gilead's Emtriva (emtricitabine) and Viread (tenofovir).

Merck pushes low-cost AIDS pill  -  Feb 17, 2007
NorthJersey.com,The tablet combines three drugs -- Gilead Sciences Inc.'s Viread and Emtriva and Bristol-Myers Squibb Co.'s Sustiva. Merck and Gilead, of Foster City,

It’s patent vs patient in AIDS fight  -  Feb 14, 2007
Economic Times,...and DNP (Delhi Network of Positive People) along with INP, have filed a pre-grant opposition to Gilead Sciences’ patent application for Viread.

Glad Tidings for Gilead  -  Feb 1, 2007
BusinessWeekThe company also sells Truvada which contains two of those three medicines and Viread which contains one. Atripla adds the Bristol-Myers Squibb (BMY) drug

Gilead Sciences Shares Peak on 4Q Profit  -  Feb 1, 2007
Houston Chronicle,Viread sales fell 13 percent to $159.5 million, and Atripla sales reached $137.4 million. Following Gilead's quarterly report, JMP Securities upgraded the

Gilead posts fourth-quarter net loss  -  Jan 31, 2007
ReutersFourth-quarter sales of Viread and Emtriva, the two older HIV drugs used in the combination pills, fell by 13 percent to $159.5 million and by 24 percent to

Gilead Sciences Posts Q4 Loss On Charges; EPS Beats View; Stock Up ...  -  Jan 31, 2007
Trading Markets,Truvada's sales increased 76% to $337.1 million for the quarter, while Viread sales dropped 13% to $159.5 million. Atripla contributed $137.4 million,

New HIV Clinical Trial To Focus On Black MSMs  -  Jan 13, 2007
247gay.com,The CDC granted $3.5 million to fund trials in San Francisco and Atlanta to test FDA-approved Viread, which also is known as tenofovir and has been shown to

National Roundup  -  Jan 17, 2007
Windy City Times,The CDC granted $3.5 million to fund trials in San Francisco and Atlanta to test the FDA-approved drug Viread, which has been shown to boost immune response

Top Picks 2007: Bill Martin "finds profits" at Gilead  -  Dec 27, 2006
Blogging StocksThe advisor explains, "Gilead is best known as a biopharmaceutical company with a leading HIV treatment franchise (Viread, Truvada, and Emtriva).

Biotech Company Not Supplying AIDS Drug As Promised, Group Charges  -  Dec 25, 2006
cybermed.it,US biotech company Gilead Sciences Inc. has been accused of breaking its promise to make its anti-AIDS drug Viread widely available in developing countries,

Gay black men wary of HIV trials in the US  -  Jan 12, 2007
The South African Star (subscription),The trial involves giving daily doses of the drug tenofovir, an anti-retroviral drug and marketed as Viread, to men. Participants, who could also be given a

Black men in focus in American HIV drug trial  -  Jan 10, 2007
Peninsula On-line,The trial involves giving daily doses of the drug tenofovir, an anti-retroviral drug made by Gilead Sciences Inc and marketed as Viread, to men.

Hana Biosciences Announces Vice President Appointments in Clinical ...  -  Jan 5, 2007
PharmaLive.com (press release),Prior to joining Hana, Dr. Choy was a Clinical Scientist at Gilead Sciences, Inc. where he was involved in the clinical development of Viread(r) for the

The ones HIV left in limbo  -  Jan 2, 2007
Los Angeles Times,...a protease inhibitor that interferes with HIV's replication process); Kaletra (three capsules twice a day; another protease inhibitor); Viread,

The Year in Review: Gilead Rises in 2006  -  Dec 27, 2006
Forbes,It combines Gilead's Truvada, which includes Viread and Emtriva, with Bristol-Myers Squibb (nyse: BMY - news - people )'s Sustiva and is the first

The Year In Review: Gilead rises in 2006  -  Dec 27, 2006
BusinessWeekIt combines Gilead's Truvada, which includes Viread and Emtriva, with Bristol-Myers Squibb's Sustiva and is the first once-a-day HIV treatment.

McGuinty Government Improves Access To Drugs  -  Dec 20, 2006
CNW Telbec (Communiqués de presse),Caduet tablets (Cardiovascular drug) - Viread (HIV/AIDS) - Aranesp (Cancer chemotherapy-related anemia) - Eprex (Cancer chemotherapy-related anemia)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional